Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control

Retrovirology

Volumn 3, Issue , 2006, Pages

  Zhou, Xue ^a   Vink, Monique ^a   Berkhout, Ben ^a   Das, Atze T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; VIRUS DNA;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; GENE EXPRESSION SYSTEM; GENE MUTATION; GENE SEQUENCE; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; PLASMID; SEQUENCE ANALYSIS; TET ON GENE REGULATORY SYSTEM; VIRUS CULTURE; VIRUS GENOME; VIRUS REPLICATION;

BINDING SITES; DOXYCYCLINE; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; GENES, BACTERIAL; GENETIC ENGINEERING; HIV-1; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; OPERATOR REGIONS, GENETIC; PHENOTYPE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33751247662     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-82     Document Type: Article

References (38)

1. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345:1342-1344.
2. Blancou P, Chenciner N, Ho Tsong FR, Monceaux V, Cumont MC, Guetard D, Hurtrel B, Wain-Hobson S: Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus. J Virol 2004, 78:1080-1092.
3. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, Glickman R, Yang J, Montefiori DC, Montelaro R, Wyand MS, Desrosiers RC: Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999, 73:4952-4961.
4. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996, 70:3724-3733.
5. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, O'Neil S, Ruprecht RM: Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003, 17:157-166.
6. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267:1820-1825.
7. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson P, Greene MF, McClure HM, Martin LN, Ruprecht RM: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5:194-203.
8. Berkhout B, Verhoef K, van Wamel JL, Back NK: Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 1999, 73:1138-1145.
9. Chakrabarti LA, Metzner KJ, Ivanovic T, Cheng H, Louis-Virelizier J, Connor RI, Cheng-Mayer C: A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol 2003, 77:1245-1256.
10. Berkhout B, Marzio G, Verhoef K: Control over HIV-1 replication by an antibiotic; a novel vaccination strategy with a drug-dependent virus. Virus Res 2002, 82:103-108.
11. Das AT, Verhoef K, Berkhout B: A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol 2004, 388:359-379.
12. Verhoef K, Marzio G, Hillen W, Bujard H, Berkhout B: Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol 2001, 75:979-987.
13. Smith SM, Khoroshev M, Marx PA, Orenstein J, Jeang KT: Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine. J Biol Chem 2001, 276:32184-32190.
14. Das AT, Zhou X, Vink M, Klaver B, Berkhout B: Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine. Expert Rev Vaccines 2002, 1:293-301.
15. Baron U, Bujard H: Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 2000, 327:401-421.
16. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H: Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
17. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000, 97:7963-7968.
18. Kiselyeva Y, Ito Y, Lima RG, Grivel JC, Das AT, Berkhout B, Margolis LB: Depletion of CD4 T lymphocytes in human lymphoid tissue infected ex vivo with doxycycline-dependent HIV-1. Virology 2004, 328:1-6.
19. Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Marzio G, Berkhout B: Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 2004, 279:18776-18782.
20. Marzio G, Vink M, Verhoef K, de Ronde A, Berkhout B: Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription. J Virol 2002, 76:3084-3088.
21. Marzio G, Verhoef K, Vink M, Berkhout B: In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc Natl Acad Sci USA 2001, 98:6342-6347.
22. Zhou X, Vink M, Klaver B, Berkhout B, Das AT: Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther 2006, 13:1382-1390.
23. Zhou X, Vink M, Klaver B, Verhoef K, Marzio G, Das AT, Berkhout B: The genetic stability of a conditional-live HIV-1 variant can be improved by mutations in the Tet-On regulatory system that restrain evolution. J Biol Chem 2006, 281:17084-17091.
24. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992, 89:5547-5551.
25. Baron U, Gossen M, Bujard H: Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res 1997, 25:2723-2729.
26. Berkhout B, Das AT, Beerens N: HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. Science 2001, 292:7.
27. Berkhout B, de Ronde A: APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 2004, 18:1861-1863.
28. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B: Initial appearance of the 18411e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997, 71:3346-3350.
29. Keulen W, Boucher C, Berkhout B: Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Res 1996, 31:45-57.
30. Orth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W: Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat Struct Biol 2000, 7:215-219.
31. Orth P, Cordes F, Schnappinger D, Hillen W, Saenger W, Hinrichs W: Conformational changes of the Tet repressor induced by tetracycline trapping. J Mol Biol 1998, 279:439-447.
32. Jeeninga RE, Van der Linden B, Jan B, Van den Berg H, Berkhout B: Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach. Cancer Res 2005, 65:3347-3355.
33. Jeeninga RE, Jan B, Van den Berg H, Berkhout B: Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology 2006, 3:64.
34. Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B: Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004, 78:12428-12437.
35. Das AT, Baldwin CE, Vink M, Berkhout B: Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry. J Virol 2005, 79:3855-3858.
36. Peden K, Emerman M, Montagnier L: Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-ILAI, HIV-IMAL, and HIV-IELI. Virology 1991, 185:661-672.
37. Auersperg N: Long-term cultivation of hypodiploid human tumor cells. J Natl Cancer Inst 1964, 32:135-163.
38. Ruijter JM, Thygesen HH, Schoneveld OJ, Das AT, Berkhout B, Lamers WH: Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology 2006, 3:2.